GPT and COVID-19: Of the moderate events, 9 cases of “COVID-19” in 9 subjects were determined to be “unlikely related” to the study drug, while the other 6 cases in 3 subjects were considered “possibly related.” These included incidents of sensory reduction, elevated aspartate aminotransferase, anemia, elevated alanine aminotransferase, upper respiratory tract infection, and muscle spasms, each occurring once.